



Ref: SEC/SE/2019-20/

Date: July 19, 2019

Scrip symbol/ code : NSE – DABUR, BSE - 500096

To,

Corporate Relation Department  
BSE Ltd

Phiroze Jeejeebhoy Towers  
Dalal Street, Mumbai- 400001

National Stock Exchange of India Ltd.

Exchange Plaza, 5th Floor

Plot No. C/1, G Block Bandra – Kurla Complex  
Bandra (E), Mumbai – 400051

**Sub: Change in Directorate of the Company**

Dear Sir(s),

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors of the Company in their meeting held today, i.e. July 19, 2019 have made following changes in the Board composition of the Company -

- 1) **Mr. Aditya Burman** (DIN: 00042277) have been appointed as an additional director, in the category of Non-Executive Promoter Director, on the Board of the Company w.e.f. July 19, 2019, subject to approval of shareholders of the Company at the ensuing Annual General meeting.

A brief profile and other details of Mr. Aditya Burman is given in the Annexure 1, as required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with the SEBI circular dated 9<sup>th</sup> September, 2015

- 2) The following Non Executive Independent Directors of the Company, whose current term of appointment is expiring, have been re-appointed on the Board of the Company for a second term of 5 (five) consecutive years, subject to approval of shareholders in the ensuing Annual General Meeting

- i) **Mrs. Falguni Sanjay Nayar** (DIN: 00003633), re-appointed w.e.f. July 28, 2019
- ii) **Mr. P N Vijay** (DIN: 00049992), re-appointed w.e.f. July 22, 2019
- iii) **Mr. R C Bhargava** (DIN: 00007620), re-appointed w.e.f. July 22, 2019
- iv) **Dr S. Narayan** (DIN: 00094081) re-appointed w.e.f. July 22, 2019
- v) **Dr. Ajay Dua** (DIN: 02318948) re-appointed w.e.f. July 22, 2019
- vi) **Mr. Sanjay Kumar Bhattacharyya** (DIN: 01924770) re-appointed w.e.f. July 22, 2019

- 3) **Dr Anand Chand Burman**, (DIN: 00056216) Chairman and Director of the Company have resigned from the office of Director of the Company and consequently have ceased to be Chairman and Director of the Company w.e.f. July 19, 2019, post Board Meeting.





- 4) **Mr. Amit Burman**, (DIN: 00042050) Vice Chairman of the Company have been appointed as Chairman of the Company and **Mr. Mohit Burman** (DIN: 21963) have been appointed as Vice Chairman of the Company w.e.f. July 19, 2019, post Board Meeting, for a period of 5 (five) years.
- 5) **Mr. Sunil Duggal**, (DIN: 00041825) Non-Executive Director of the Company have resigned from the office of Director of the Company and consequently have ceased to be Director of the Company w.e.f. July 19, 2019, post Board Meeting.

It is further informed that to the best of our knowledge and information the directors appointed/ re-appointed mentioned in Point No. 1 & 2 above have not been debarred from holding the office of a Director by virtue of any Order of SEBI or any other such authority.

Thanking You,

Yours faithfully,

For Dabur India Limited

(A.K Jain)

EVP (Finance) and Company Secretary

Encl: as above

## Mr. Aditya Burman

Sl.No.	Particulars	Disclosures
1.	Reason for change	Appointment as additional director in the category of Non- Executive Promoter Director on the Board of the Company
2.	Date of appointment and terms of appointment	Appointment as additional director in the category of Non- Executive Promoter Director of the Company with effect from July 19, 2019, subject to approval of shareholders of the Company at the ensuing Annual General meeting
3.	Brief profile	<p>Mr Aditya Burman returned to India after completing his studies in 2003 and joined as an intern at Dabur Pharma Limited, a family-owned Oncology-focussed Pharmaceutical firm. Fuelled with grit and perseverance, Aditya worked towards expanding the company's footprint in the overseas markets and was soon in charge of its Sales and Marketing in Latin America. Under his stewardship, Dabur Pharma emerged as a leading research-driven pharmaceutical firm with a global presence. The company was subsequently sold to Fresenius Kabi in 2008.</p> <p>He is also a Director on the board of Oncquest Laboratories Ltd., a Clinical Pathology and Molecular Diagnostics company with a focus in Oncology and Genetics. After the sale of Dabur Pharma, Aditya focussed his energy on building Oncquest as the preferred reference laboratory for physicians, hospitals and research bodies. He was also instrumental in streamlining operations, strengthening its research function, and giving it a pan-India presence to drive growth.</p> <p>He also serves on the board of Dabur Nepal Pvt Ltd, besides being the President of the Delhi Chapter of Entrepreneurs' Organization, a global network exclusively for entrepreneurs.</p> <p>Born in January 1980, Aditya lives in Delhi and has also been supporting several charities in the health care and health awareness space. He has also been involved with agencies in supporting children suffering from Cancer.</p>
4.	Disclosure of relationships between directors of the Company	None


